Possible New Combination Treatment for Cancer
New molecule
Jonas Nilsson and his research group have developed, in collaboration with the Canadian company Zenith epigenetics, a new molecule known as “RVX2135”, which has been tested in mice with MYC-driven lymphoma. The study will be published this week in the early edition of the prestigious scientific journal PNAS and shows that the new molecule not only causes cancer cells in culture to stop growing, it also causes tumors to die. This means that the mice survive their cancer longer.
“We hypothesized that the new molecule could also switch off the MYC gene. However, our studies show that neither the JQ1 molecule nor the RVX2135 molecule have this property in these types of cells. This means that the mode of action is probably not as simple as we believed,” says Jonas Nilsson, Group Leader at the Sahlgrenska Cancer Center.
Increased survival in mice
The scientists in Gothenburg also discovered that the RVX2135 molecule activates the same genes as those activated by molecules known as “HDAC inhibitors”, which are already used to treat cancer. The scientists then tested HDAC inhibitors together with the newly discovered molecules and it turned out that the combination increased survival in mice with lymphoma.
“It was also possible to reduce the dose of HDAC inhibitors when used in combination with RVX2135 and this reduced adverse effects. We see this as a breakthrough in the clinical development of this type of treatment,” Jonas Nilsson explains.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.